{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:21:25Z","timestamp":1793762485901,"version":"4.6.1"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T00:00:00Z","timestamp":1524096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1093\/jjco\/hyy053","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T11:09:28Z","timestamp":1522840168000},"page":"503-513","source":"Crossref","is-referenced-by-count":137,"title":["Drug review: Pazopanib"],"prefix":"10.1093","volume":"48","author":[{"given":"Shingo","family":"Miyamoto","sequence":"first","affiliation":[{"name":"Department of Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Kakutani","sequence":"additional","affiliation":[{"name":"Department of Urology, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Urology, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Hanashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Urology, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,19]]},"reference":[{"key":"key\n\t\t\t\t20180530042945_hyy053C1","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic\u2013pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"key\n\t\t\t\t20180530042945_hyy053C2","first-page":"13","volume-title":"WHO Classification of Tumors of Soft Tissue and Bone","author":"Fletcher","year":"2013","edition":"4th edn"},{"key":"key\n\t\t\t\t20180530042945_hyy053C3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"key\n\t\t\t\t20180530042945_hyy053C4","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/cncr.26415","article-title":"Systemic therapy for advanced soft-tissue sarcomas: highlighting novel therapies and treatment approaches","volume":"118","author":"Riedel","year":"2012","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C5","first-page":"560","article-title":"Cell proliferation in human soft-tissue tumors correlates with platelet-derived growth factor B chain expression: an immunohistochemical and in situ hybridization study","volume":"54","author":"Wang","year":"1994","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t20180530042945_hyy053C6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00432-003-0504-0","article-title":"Determination of vascular endothelial growth factor (VEGF) overexpression in soft-tissue sarcomas and the role of overexpression in leiomyosarcoma","volume":"130","author":"Potti","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C7","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s10434-001-0260-9","article-title":"Vascular endothelial growth factor and soft-tissue sarcomas: tumor expression correlates with grade","volume":"8","author":"Chao","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C8","first-page":"3591","article-title":"Expression of vascular endothelial growth factor and its receptor, KDR\/Flk-1, in soft-tissue sarcomas","volume":"25","author":"Pakos","year":"2005","journal-title":"Anticancer Res"},{"key":"key\n\t\t\t\t20180530042945_hyy053C9","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1200\/JCO.2005.01.186","article-title":"Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma","volume":"23","author":"Rini","year":"2005","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/annonc\/mdi182","article-title":"Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor","volume":"16","author":"Hara","year":"2005","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","article-title":"Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer","volume":"12","author":"Thomas","year":"2006","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20180530042945_hyy053C12","author":"Votrient prescribing information"},{"key":"key\n\t\t\t\t20180530042945_hyy053C13","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/jor.22091","article-title":"A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway","volume":"30","author":"Hosaka","year":"2012","journal-title":"J Orthop Res"},{"key":"key\n\t\t\t\t20180530042945_hyy053C14","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20180530042945_hyy053C15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00280-014-2374-3","article-title":"Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors","volume":"73","author":"Inada-Inoue","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1055\/s-0033-1363274","article-title":"Acute aortic dissection in a patient receiving multiple tyrosine kinase inhibitors for 5 years","volume":"45","author":"Funahashi","year":"2014","journal-title":"Aktuelle Urol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C17","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.2012.47.0914","article-title":"Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft-tissue sarcoma and other refractory solid tumors: a children\u2019s oncology group phase I consortium report","volume":"31","author":"Glade Bender","year":"2013","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C18","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1158\/1078-0432.CCR-12-3214","article-title":"Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study","volume":"19","author":"Shibata","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20180530042945_hyy053C19","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","article-title":"Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft-tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft-tissue and bone sarcoma group (EORTC study 62043)","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C20","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1002\/cncr.30926","article-title":"Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma","volume":"123","author":"Samuels","year":"2017","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C21","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180530042945_hyy053C22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jjco\/hyv184","article-title":"A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft-tissue sarcoma: results from the Japanese subgroup","volume":"46","author":"Kawai","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C23","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1002\/cncr.29426","article-title":"Health-related quality-of-life results from PALETTE: a randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft-tissue sarcoma whose disease has progressed during or after prior chemotherapy \u2013 a European Organization for research and treatment of cancer soft-tissue and bone sarcoma group global network study (EORTC 62072)","volume":"121","author":"Coens","year":"2015","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C25","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C26","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a Phase III Randomized Multicenter Clinical Trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study","volume":"8","author":"Grosso","year":"2007","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C28","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180530042945_hyy053C29","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.2016.71.6605","article-title":"Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized Phase III study of eribulin versus dacarbazine","volume":"35","author":"Demetri","year":"2017","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.tranon.2014.09.007","article-title":"Pazopanib, a receptor tyrosine kinase inhibitor, suppresses tumor growth through angiogenesis in dedifferentiated liposarcoma xenograft models","volume":"7","author":"Li","year":"2014","journal-title":"Transl Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C31","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/cncr.29961","article-title":"The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft-tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study","volume":"122","author":"Nakamura","year":"2016","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C32","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/annonc\/mdt586","article-title":"Long-term responders and survivors on pazopanib for advanced soft-tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072","volume":"25","author":"Kasper","year":"2014","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C33"},{"key":"key\n\t\t\t\t20180530042945_hyy053C34","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0959-8049(03)00264-8","article-title":"Chemotherapy in alveolar soft part sarcomas. What do we know?","volume":"39","author":"Reichardt","year":"2003","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C35","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/annonc\/mdq644","article-title":"Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect","volume":"22","author":"Stacchiotti","year":"2011","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1634\/theoncologist.2017-0161","article-title":"Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma","volume":"23","author":"Stacchiotti","year":"2017","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t20180530042945_hyy053C37","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","article-title":"Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study","volume":"26","author":"Penel","year":"2008","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","article-title":"Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis","volume":"56","author":"Koll\u00e1r","year":"2017","journal-title":"Acta Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C40","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.clgc.2013.04.006","article-title":"Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial","volume":"11","author":"Hainsworth","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C41","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C42","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180530042945_hyy053C43","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/bjc.2014.503","article-title":"Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma","volume":"111","author":"Suttle","year":"2014","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C44","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/FTD.0000000000000141","article-title":"Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study","volume":"37","author":"de Wit","year":"2015","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t20180530042945_hyy053C45","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/clpt.2010.199","article-title":"A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors","volume":"88","author":"Heath","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180530042945_hyy053C46","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C47","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000366227","article-title":"An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma","volume":"87","author":"Sternberg","year":"2014","journal-title":"Oncology"},{"key":"key\n\t\t\t\t20180530042945_hyy053C48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejca.2011.05.017","article-title":"Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial","volume":"48","author":"Cella","year":"2012","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180530042945_hyy053C50","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C51","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/sj.bjc.6605366","article-title":"Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors","volume":"101","author":"Kumar","year":"2009","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C52","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJMc1400731","article-title":"Overall survival in renal-cell carcinoma with pazopanib versus sunitinib","volume":"370","author":"Motzer","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180530042945_hyy053C53","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/cncr.29888","article-title":"Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma","volume":"122","author":"Beaumont","year":"2016","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C54","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study","volume":"32","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C55","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1200\/JCO.2017.73.5324","article-title":"Randomized Phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma","volume":"35","author":"Motzer","year":"2017","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C56","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","article-title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"387","author":"Haas","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180530042945_hyy053C57","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180530042945_hyy053C58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2016.06.016","article-title":"First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"65","author":"Ruiz-Morales","year":"2016","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C59","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2016.05.049","article-title":"Third-line targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"71","author":"Wells","year":"2017","journal-title":"Eur Urol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C60","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/bjc.2013.119","article-title":"Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000\u20132008)","volume":"108","author":"Wahlgren","year":"2013","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C61","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180530042945_hyy053C62","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fonc.2014.00070","article-title":"Control of the immune response by pro-angiogenic factors","volume":"4","author":"Voron","year":"2014","journal-title":"Front Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C63","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ejca.2015.04.026","article-title":"Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)","volume":"51","author":"O\u2019Brien","year":"2015","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C64","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.ejca.2015.03.019","article-title":"Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients","volume":"51","author":"Powles","year":"2015","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C65","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/sj.bjc.6605653","article-title":"Pazopanib-induced hyperbilirubinemia is associated with Gilbert\u2019s syndrome UGT1A1 polymorphism","volume":"102","author":"Xu","year":"2010","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C66","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20180530042945_hyy053C67","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1093\/annonc\/mds179","article-title":"Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib","volume":"23","author":"George","year":"2012","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C68","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1634\/theoncologist.2012-0339","article-title":"Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies","volume":"18","author":"Hurwitz","year":"2013","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t20180530042945_hyy053C69","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1016\/j.ejca.2015.08.002","article-title":"Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft-tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials","volume":"51","author":"Duffaud","year":"2015","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C70","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejca.2015.10.006","article-title":"Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced\/metastatic renal cell carcinoma?","volume":"53","author":"Goldstein","year":"2016","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180530042945_hyy053C71","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1378\/chest.09-2292","article-title":"A comprehensive review of spontaneous pneumothorax complicating sarcoma","volume":"138","author":"Hoag","year":"2010","journal-title":"Chest"},{"key":"key\n\t\t\t\t20180530042945_hyy053C72","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-3329-4-14","article-title":"Pneumothorax as adverse event in patients with lung metastases of soft-tissue sarcoma treated with pazopanib: a single reference centre case series","volume":"4","author":"Verschoor","year":"2014","journal-title":"Clin Sarcoma Res"},{"key":"key\n\t\t\t\t20180530042945_hyy053C73","doi-asserted-by":"crossref","first-page":"481071","DOI":"10.1155\/2014\/481071","article-title":"Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in the United kingdom","volume":"2014","author":"Amdahl","year":"2014","journal-title":"Sarcoma"},{"key":"key\n\t\t\t\t20180530042945_hyy053C74","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12094-014-1191-9","article-title":"Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft-tissue sarcoma in Spain","volume":"17","author":"Villa","year":"2015","journal-title":"Clin Transl Oncol"},{"key":"key\n\t\t\t\t20180530042945_hyy053C75","doi-asserted-by":"crossref","first-page":"e0175920","DOI":"10.1371\/journal.pone.0175920","article-title":"Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom","volume":"12","author":"Amdahl","year":"2017","journal-title":"PLoS One"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/48\/6\/503\/24963530\/hyy053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T02:53:17Z","timestamp":1571021597000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/48\/6\/503\/4978098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,19]]},"references-count":75,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,4,19]]},"published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyy053","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6]]},"published":{"date-parts":[[2018,4,19]]}}}